CEA

Revol Greens Pioneers in Selecting IUNU as Advanced Technology Partner to Drive Higher Yield, Sustainable Greenhouse Lettuce at Scale

Retrieved on: 
Monday, June 20, 2022

OWATONNA, Minn., June 20, 2022 /PRNewswire-PRWeb/ -- Revol Greens, America's largest greenhouse lettuce grower, announced today that it has chosen IUNU as its technology partner to deliver a fully integrated approach of artificial intelligence, digital solutions, and automation at scale to meet rising consumer demand for greenhouse-grown leafy greens. Revol Greens is the only greenhouse operation to connect learned AI technologies with their proprietary organic cultivation program.

Key Points: 
  • Revol Greens is the only greenhouse operation to connect learned AI technologies with their proprietary organic cultivation program.
  • As part of this commitment, Revol Greens is executing an ambitious digital strategy and quickly becoming the global leader in automated and advanced greenhouse operations.
  • IUNU's LUNA Platform is the most advanced horticultural platform on the market and helps greenhouse operators drive higher yields and produce better crops.
  • Revol Greens adopts the most advanced greenhouse technology and growing methods in the industry, including facilities that use 90 percent less water than traditional field-grown greens, irrigation from UV-sterilized water, and sustainable sunlight.

Little Leaf Farms Raises $300 Million in Capital with Financing from TPG's The Rise Fund and Bank of America

Retrieved on: 
Wednesday, June 15, 2022

DEVENS, Mass. and SAN FRANCISCO, June 15, 2022 /PRNewswire/ -- Little Leaf Farms, the country's #1 brand of packaged lettuce sustainably grown through controlled environment agriculture (CEA), has raised $300 million in new capital, with equity financing led by The Rise Fund, TPG's multi-sector global impact investing strategy, and debt funding from Bank of America. The capital will support aggressive growth and expansion of farms and distribution, making Little Leaf Farms' local lettuces accessible to more than half of the country's population by 2026. Immediate expansion and a doubling of acreage comes with the opening of a new greenhouse in McAdoo, Pennsylvania this summer.

Key Points: 
  • The capital will support aggressive growth and expansion of farms and distribution, making Little Leaf Farms' local lettuces accessible to more than half of the country's population by 2026.
  • As part of this transaction, Maya Chorengel, Co-Managing Partner of The Rise Funds, will join Little Leaf Farms' Board of Directors.
  • "This funding from our partners at The Rise Funds and Bank of America marks a pivotal moment in Little Leaf Farms' growth story," said Paul Sellew, Founder and CEO of Little Leaf Farms.
  • The capital raise includes support from Bank of America, an early debt investor in Little Leaf Farms that helped fuel the brand's success and growth throughout the Northeast.

IMAGING ENDPOINTS EXPANDS LEADERSHIP IN BIG DATA ANALYSIS, RADIOMICS, AND AI

Retrieved on: 
Wednesday, June 15, 2022

SCOTTSDALE, Ariz., June 15, 2022 /PRNewswire/ -- Imaging Endpoints (IE), an imaging CRO (iCRO) that provides comprehensive central imaging services and technology solutions throughout the clinical trial process, announced that the United States Patent and Trademark Office (USPTO) has approved the patent for Imaging Endpoints' Proprietary Medical Imaging System (Patent 11361020).

Key Points: 
  • Imaging Endpoints was issued the patent today, allowing all twenty of the submitted claims for its Proprietary Medical Imaging System that provides an industry-leading approach for optimizing large imaging datasets to enable radiomic and other research.
  • Imaging Endpoints' Proprietary System contains multiple interconnecting processes and technological solutions that prioritize efficiency and data security.
  • "We will continue to push the boundaries of imaging science in our mission to revolutionize the data an imaging CRO can provide."
  • Imaging Endpoints (IE) is an imaging research and core laboratory that provides comprehensive imaging CRO (iCRO) services and technology solutions throughout the clinical trial process.

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

Retrieved on: 
Wednesday, June 15, 2022

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc.(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR system in the treatment of standard surgical risk patients with carotid artery disease.

Key Points: 
  • SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc.(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR system in the treatment of standard surgical risk patients with carotid artery disease.
  • ROADSTER 3 is a prospective, multi-center, single-arm study designed to assess the real-world treatment of standard surgical risk patients with carotid artery disease using TCAR.
  • This study is providing physicians with the unique opportunity to participate in a first-ever prospective study to demonstrate the safety and efficacy of TCAR among the standard surgical risk patient population, said Dr. Jeffrey Jim.
  • Silk Road Medical, Inc. (NASDAQ: SILK),is a medical device company located inSunnyvale, California and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact.

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Retrieved on: 
Tuesday, June 14, 2022

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).
  • FAP-2286 is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP to enter clinical development and is the lead candidate in Clovis Oncologys targeted radionuclide therapy (TRT) development program.
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).

Vascular Quality Initiative (SVS VQI) Announces the Expansion of Medicare Coverage to Standard Surgical Risk Patients within their TCAR Surveillance Project

Retrieved on: 
Tuesday, June 14, 2022

The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services (CMS) has expanded coverage for Transcarotid Artery Revascularization (TCAR) to include standard surgical risk patients within the VQI TCAR Surveillance Project.

Key Points: 
  • The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services (CMS) has expanded coverage for Transcarotid Artery Revascularization (TCAR) to include standard surgical risk patients within the VQI TCAR Surveillance Project.
  • Launched in 2016 by the SVS PSO, the TCAR Surveillance Project uses real-world registry data to evaluate the safety and effectiveness of TCAR against the standard of care, carotid endarterectomy (CEA).
  • The CMS expansion of coverage decision will extend TCAR to standard risk patients in addition to high-risk patients who are currently covered under the TSP.
  • Reimbursement for TCAR within the TCAR Surveillance Project will now apply to Medicare beneficiaries who are deemed to be at high risk and standard risk for adverse events from CEA.

IntraLight™ Launches Next-Gen Pesticide, Protecting Crops Without Chemicals

Retrieved on: 
Tuesday, June 14, 2022

BOULDER, Colo., June 14, 2022 /PRNewswire/ -- IntraLight, a Boulder based startup, has completed development of its light treatment technology that automatically protects crops from pests and pathogens with daily light treatments. Using a proprietary spectrum IntraLights severely damage pest and pathogen DNA, destroying their ability to grow and reproduce. This new crop protection technology replaces chemical pesticides, removing material and labor expenses while allowing growers to capture the increased value of organic produce. IntraLight has opened pre-orders for their first offering, their #5 ring light, capable of treating 64 ft3 above each unit.

Key Points: 
  • This new crop protection technology replaces chemical pesticides, removing material and labor expenses while allowing growers to capture the increased value of organic produce.
  • IntraLight has opened pre-orders for their first offering, their #5 ring light , capable of treating 64 ft3 above each unit.
  • As organic food purchases in the US pass $60 billion growers will need solutions to convert to organic production easily and effectively.
  • Light treatment technology is the only crop protection method able to protect crops for years with a single upfront expense.

National Hispanic Energy Policy Council Launches at Puerto Rican Summit in Orlando

Retrieved on: 
Friday, June 10, 2022

The National Hispanic Energy Policy Council launched on Friday to advocate for affordable, reliable energy and highlight the outsized energy burden faced by Hispanic families in the U.S., The Florida State Hispanic Chamber of Commerce (FSHCC) announced on Friday.

Key Points: 
  • The National Hispanic Energy Policy Council launched on Friday to advocate for affordable, reliable energy and highlight the outsized energy burden faced by Hispanic families in the U.S., The Florida State Hispanic Chamber of Commerce (FSHCC) announced on Friday.
  • FSHCC CEO and President Julio Fuentes will chair the council, while CEA Southwest Director Matthew Gonzales will serve as vice chair from New Mexico.
  • CEA looks forward to working with the council to help educate elected leaders, policy makers and the Hispanic public on what good energy policy choices look like, in an era when Americas energy policy is clearly broken.
  • The Florida State Hispanic Chamber of Commerce was founded in 2000 in response to the tremendous growth of Floridas Hispanic population.

CEA Industries Subsidiary, Surna Cultivation Technologies, to Exhibit at Upcoming June and July Conferences

Retrieved on: 
Thursday, June 2, 2022

Brandy Keen, Surna Co-founder and Senior Technical Advisor, will join the panel, Driving Profitability and Sustainability through Greater Energy Efficiency at 11:30 a.m. EST, June 23rd.

Key Points: 
  • Brandy Keen, Surna Co-founder and Senior Technical Advisor, will join the panel, Driving Profitability and Sustainability through Greater Energy Efficiency at 11:30 a.m. EST, June 23rd.
  • Tony McDonald, CEA Industries Chairman and CEO as well as Jon Kozlowski, Surnas VP of Sales, will also be attending.
  • CannaOne , Biloxi, MS, July 7-9: Surna will be present for one of the only events scheduled this year in this upcoming medical cannabis market.
  • Surna Cultivation Technologies ( www.surna.com ), is an industry leader in CEA facility design and technologies.

Bradley Nattrass, Chairman and CEO at urban-gro, Inc., Honored as a 2022 Colorado Titan 100

Retrieved on: 
Thursday, June 2, 2022

The Titan 100 honorees will be published in a limited-edition Titan 100 book and profiled online.

Key Points: 
  • The Titan 100 honorees will be published in a limited-edition Titan 100 book and profiled online.
  • They will also receive recognition in ColoradoBiz Magazine and at the Titan 100 Annual Awards Ceremony.
  • Mr. Nattrass has served as the Chairman and CEO of urban-gro since co-founding the Company in 2014.
  • The Colorado Titan 100 Annual Awards Ceremony will be held tonight, June 2, 2022, in Denver.